Teva anticipates EBITDA recovery post-2025 as Austedo and Uzedy grow and generic Revlimid faces rising competition.

Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, ...

Mallinckrodt & Endo complete merger to create global, scaled, diversified therapeutics leader: Dublin Saturday, August 2, 2025, 09:00 Hrs [IST] Mallinckrodt plc, a leading provide ...

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...

Graeme Duncan from ADVANZ PHARMA explores how successful cross-industry collaboration between pharma and generics companies has helped support supply challenges during the pandemic.

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

Says “exciting time” for biosimilars. Sees ~$700M of net savings by 2027 with two thirds expected to be realized by 2026. Expects portfolio to ...

Among those celebrating today’s agreement on a voluntary rebate scheme for branded medicines in the UK, there are dissenting voices, including a group representing manufacturers of off-patent ...

Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and ...

Teva’s chief drug Austedo—approved in Huntington’s disease and tardive dyskinesia—grew sales 19% to $498 million for the ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...